![]() |
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Fusion gene ID: 27431 |
FusionGeneSummary for PLA2G16_SGPP2 |
![]() |
Fusion gene information | Fusion gene name: PLA2G16_SGPP2 | Fusion gene ID: 27431 | Hgene | Tgene | Gene symbol | PLA2G16 | SGPP2 | Gene ID | 11145 | 130367 |
Gene name | phospholipase A2 group XVI | sphingosine-1-phosphate phosphatase 2 | |
Synonyms | AdPLA|H-REV107|H-REV107-1|HRASLS3|HREV107|HREV107-1|HREV107-3|HRSL3 | SPP2|SPPase2 | |
Cytomap | 11q12.3-q13.1 | 2q36.1 | |
Type of gene | protein-coding | protein-coding | |
Description | HRAS-like suppressor 3Ca-independent phospholipase A1/2H-rev 107 protein homologHRAS-like suppressor 1adipose-specific PLA2adipose-specific phospholipase A2group XVI phospholipase A1/A2group XVI phospholipase A2renal carcinoma antigen NY-REN-65 | sphingosine-1-phosphate phosphatase 2sphingosine 1-phosphate phosphohydrolase 2sphingosine-1-phosphatase 2sphingosine-1-phosphate phosphotase 2 | |
Modification date | 20180519 | 20180329 | |
UniProtAcc | P53816 | Q8IWX5 | |
Ensembl transtripts involved in fusion gene | ENST00000323646, ENST00000415826, ENST00000394613, | ENST00000321276, | |
Fusion gene scores | * DoF score | 3 X 3 X 3=27 | 4 X 2 X 4=32 |
# samples | 3 | 5 | |
** MAII score | log2(3/27*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(5/32*10)=0.643856189774725 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
Context | PubMed: PLA2G16 [Title/Abstract] AND SGPP2 [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation | Tumor suppressor gene involved fusion gene, in-frame but not retained their domain. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | PLA2G16 | GO:0006644 | phospholipid metabolic process | 20100577 |
Tgene | SGPP2 | GO:0006670 | sphingosine metabolic process | 12411432 |
![]() (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
TCGA | RV | LGG | TCGA-TM-A84B-01A | PLA2G16 | chr11 | 63357572 | - | SGPP2 | chr2 | 223339287 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
In-frame | ENST00000323646 | ENST00000321276 | PLA2G16 | chr11 | 63357572 | - | SGPP2 | chr2 | 223339287 | + |
Frame-shift | ENST00000415826 | ENST00000321276 | PLA2G16 | chr11 | 63357572 | - | SGPP2 | chr2 | 223339287 | + |
5UTR-3CDS | ENST00000394613 | ENST00000321276 | PLA2G16 | chr11 | 63357572 | - | SGPP2 | chr2 | 223339287 | + |
Top |
FusionProtFeatures for PLA2G16_SGPP2 |
![]() |
Hgene | Tgene |
PLA2G16 | SGPP2 |
Lipid-modifying enzyme that acts as major regulator ofadipocyte lipolysis by catalyzing the release of fatty acids fromphospholipids in adipose tissue (PubMed:19615464, PubMed:19047760,PubMed:20837014, PubMed:22605381, PubMed:22923616). Showsphospholipase A1 and A2 activity, catalyzing the calcium-independent hydrolysis of acyl groups in variousphosphatidylcholines (PC) and phosphatidylethanolamine (PE)(PubMed:19615464, PubMed:19047760, PubMed:20837014,PubMed:22605381, PubMed:22923616). For most substrates,phospholipase A1 activity is much higher than phospholipase A2activity (PubMed:19047760). Phospholipase activity causesdecreased intracellular levels of ether-type lipids, affectingperoxisome metabolism (By similarity). May also haveacyltransferase activity: catalyzes both N-acylation ofphosphatidylethanolamine to form N-acyl-phosphatidylethanolamineand O-acylation of lyso-phosphatidylcholines to formphosphatidylcholines (PubMed:22605381, PubMed:25383759). Therelevance of acyltransferase activity in vivo is however unclearand would require additional evidences (PubMed:22605381,PubMed:25383759). Also has weak lysophospholipase activity (Bysimilarity). {ECO:0000250|UniProtKB:Q8R3U1,ECO:0000269|PubMed:17374643, ECO:0000269|PubMed:19047760,ECO:0000269|PubMed:19615464, ECO:0000269|PubMed:20837014,ECO:0000269|PubMed:22605381, ECO:0000269|PubMed:22923616,ECO:0000269|PubMed:25383759}. (Microbial infection) Acts as a host factor forpicornaviruses: required during early infection to promote viralgenome release into the cytoplasm (PubMed:28077878). May act as acellular sensor of membrane damage at sites of virus entry, whichrelocalizes to sites of membrane rupture upon virus unfection(PubMed:28077878). Facilitates safe passage of the RNA away fromLGALS8, enabling viral genome translation by host ribosome(PubMed:28077878). May also be involved in initiating poreformation, increasing pore size or in maintaining pores for genomedelivery (PubMed:28077878). The lipid-modifying enzyme activity isrequired for this process (PubMed:28077878).{ECO:0000269|PubMed:28077878}. | Has specific phosphohydrolase activity towards sphingoidbase 1-phosphates. Has high phosphohydrolase activity againstdihydrosphingosine-1-phosphate and sphingosine-1-phosphate (S1P)in vitro. May play a role in attenuating intracellular sphingosine1-phosphate (S1P) signaling. May play a role in pro-inflammatorysignaling. {ECO:0000269|PubMed:12411432,ECO:0000269|PubMed:17113265}. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | PLA2G16 | chr11:63357572 | chr2:223339287 | ENST00000323646 | - | 3 | 4 | 1_132 | 129 | 163 | Topological domain | Cytoplasmic |
Hgene | PLA2G16 | chr11:63357572 | chr2:223339287 | ENST00000415826 | - | 4 | 5 | 1_132 | 129 | 163 | Topological domain | Cytoplasmic |
Tgene | >SGPP2 | chr11:63357572 | chr2:223339287 | ENST00000321276 | + | 0 | 5 | 136_144 | 73 | 400 | Region | Phosphatase sequence motif I |
Tgene | >SGPP2 | chr11:63357572 | chr2:223339287 | ENST00000321276 | + | 0 | 5 | 163_166 | 73 | 400 | Region | Phosphatase sequence motif II |
Tgene | >SGPP2 | chr11:63357572 | chr2:223339287 | ENST00000321276 | + | 0 | 5 | 206_217 | 73 | 400 | Region | Phosphatase sequence motif III |
Tgene | >SGPP2 | chr11:63357572 | chr2:223339287 | ENST00000321276 | + | 0 | 5 | 121_141 | 73 | 400 | Transmembrane | Helical |
Tgene | >SGPP2 | chr11:63357572 | chr2:223339287 | ENST00000321276 | + | 0 | 5 | 160_180 | 73 | 400 | Transmembrane | Helical |
Tgene | >SGPP2 | chr11:63357572 | chr2:223339287 | ENST00000321276 | + | 0 | 5 | 185_205 | 73 | 400 | Transmembrane | Helical |
Tgene | >SGPP2 | chr11:63357572 | chr2:223339287 | ENST00000321276 | + | 0 | 5 | 219_239 | 73 | 400 | Transmembrane | Helical |
Tgene | >SGPP2 | chr11:63357572 | chr2:223339287 | ENST00000321276 | + | 0 | 5 | 247_267 | 73 | 400 | Transmembrane | Helical |
Tgene | >SGPP2 | chr11:63357572 | chr2:223339287 | ENST00000321276 | + | 0 | 5 | 280_300 | 73 | 400 | Transmembrane | Helical |
Tgene | >SGPP2 | chr11:63357572 | chr2:223339287 | ENST00000321276 | + | 0 | 5 | 318_338 | 73 | 400 | Transmembrane | Helical |
Tgene | >SGPP2 | chr11:63357572 | chr2:223339287 | ENST00000321276 | + | 0 | 5 | 371_391 | 73 | 400 | Transmembrane | Helical |
Tgene | >SGPP2 | chr11:63357572 | chr2:223339287 | ENST00000321276 | + | 0 | 5 | 88_108 | 73 | 400 | Transmembrane | Helical |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | >PLA2G16 | chr11:63357572 | chr2:223339287 | ENST00000323646 | - | 3 | 4 | 156_162 | 129 | 163 | Topological domain | Lumenal |
Hgene | >PLA2G16 | chr11:63357572 | chr2:223339287 | ENST00000415826 | - | 4 | 5 | 156_162 | 129 | 163 | Topological domain | Lumenal |
Hgene | >PLA2G16 | chr11:63357572 | chr2:223339287 | ENST00000323646 | - | 3 | 4 | 133_155 | 129 | 163 | Transmembrane | Helical |
Hgene | >PLA2G16 | chr11:63357572 | chr2:223339287 | ENST00000415826 | - | 4 | 5 | 133_155 | 129 | 163 | Transmembrane | Helical |
Top |
FusionGeneSequence for PLA2G16_SGPP2 |
![]() (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
>In-frame_PLA2G16_ENST00000323646_chr11_63357572_-_SGPP2_ENST00000321276_chr2_223339287_+_456aa MRAPIPEPKPGDLIEIFRPFYRHWAIYVGDGYVVHLAPPSEVAGAGAASVMSALTDKAIVKKELLYDVAGSDKYQVNNKHDDKYSPLPCS KIIQRAEELVGQEVLYKLTSENCEHFVNELRYGVARSDQAYVQKYVVKNYFYYYLFQFSAALGQEVFYITFLPFTHWNIDPYLSRRLIII WVLVMYIGQVAKDVLKWPRPSSPPVVKLEKRLIAEYGMPSTHAMAATAIAFTLLISTMDRYQYPFVLGLVMAVVFSTLVCLSRLYTGMHT VLDVLGGVLITALLIVLTYPAWTFIDCLDSASPLFPVCVIVVPFFLCYNYPVSDYYSPTRADTTTILAAGAGVTIGFWINHFFQLVSKPA ESLPVIQNIPPLTTYMLVLGLTKFAVGIVLILLVRQLVQNLSLQVLYSWFKVVTRNKEARRRLEIEVPYKFVTYTSVGICATTFVPMLHR |
* Fusion transcript sequences (only coding sequence (CDS) region). |
>In-frame_PLA2G16_ENST00000323646_chr11_63357572_-_SGPP2_ENST00000321276_chr2_223339287_+_1368nt ATGCGTGCGCCCATTCCAGAGCCTAAGCCTGGAGACCTGATTGAGATTTTTCGCCCTTTCTACAGACACTGGGCCATCTATGTTGGCGAT GGATATGTGGTTCATCTGGCCCCTCCAAGTGAGGTCGCAGGAGCTGGTGCAGCCAGTGTCATGTCCGCCCTGACTGACAAGGCCATCGTG AAGAAGGAATTGCTGTATGATGTGGCCGGGAGTGACAAGTACCAGGTCAACAACAAACATGATGACAAGTACTCGCCGCTGCCCTGCAGC AAAATCATCCAGCGGGCGGAGGAGCTGGTGGGGCAGGAGGTGCTCTACAAGCTGACCAGTGAGAACTGCGAGCACTTTGTGAATGAGCTG CGCTATGGAGTCGCCCGCAGTGACCAGGCTTATGTACAGAAGTACGTCGTGAAGAATTATTTCTACTATTACCTATTCCAATTTTCAGCT GCTTTGGGCCAAGAAGTGTTCTACATCACGTTTCTTCCATTCACTCACTGGAATATTGACCCTTATTTATCCAGAAGATTGATCATCATA TGGGTTTTGGTGATGTATATTGGCCAAGTGGCCAAGGATGTCTTGAAGTGGCCCCGTCCCTCCTCCCCTCCAGTTGTAAAACTGGAAAAG AGACTGATCGCTGAATATGGAATGCCATCCACCCACGCCATGGCGGCCACTGCCATTGCCTTCACCCTCCTTATCTCTACTATGGACAGA TACCAGTATCCATTTGTGTTGGGACTGGTGATGGCCGTGGTGTTTTCCACCTTGGTGTGTCTCAGCAGGCTCTACACTGGGATGCATACG GTCCTGGATGTGCTGGGTGGCGTCCTGATCACCGCACTCCTCATCGTCCTCACCTACCCTGCCTGGACCTTCATCGACTGCCTGGACTCG GCCAGCCCCCTCTTCCCCGTGTGTGTCATAGTTGTGCCATTCTTCCTGTGTTACAATTACCCTGTTTCTGATTACTACAGCCCAACCCGG GCGGACACCACCACCATTCTGGCTGCCGGGGCTGGAGTGACCATAGGATTCTGGATCAACCATTTCTTCCAGCTTGTATCCAAGCCCGCT GAATCTCTCCCTGTTATTCAGAACATCCCACCACTCACCACCTACATGTTAGTTTTGGGTCTGACCAAATTTGCAGTGGGAATTGTGTTG ATCCTCTTGGTTCGTCAGCTTGTACAAAATCTCTCACTGCAAGTATTATACTCATGGTTCAAGGTGGTCACCAGGAACAAGGAGGCCAGG CGGAGACTGGAGATTGAAGTGCCTTACAAGTTTGTTACCTACACATCTGTTGGCATCTGCGCTACAACCTTTGTGCCGATGCTTCACAGG |
* Fusion transcript sequences (Full-length transcript). |
>In-frame_PLA2G16_ENST00000323646_chr11_63357572_-_SGPP2_ENST00000321276_chr2_223339287_+_3773nt CTTCCTGGAAGGGTGCGATAAGGCCGGGCGAGGTGCCTGGGATGCTTCTCCCCTTCCGCGAGGAAGAGATCTAATTGGGTAGGGCGGGTG TAGACTAGCCTGCCGAGCCGCCCGCTGGCACCTGCAGCCTCCTGGGCGCCCGCCGGGCCCCGGCGAGAAAGTTGTTAAAGGGAGCGAGGT GGTTGTTCCTGGGGTCCGAGGCGCGCCTCTCACGCCCTGCCCAACAGAAGCCGCAGTCCCGTGGGGTCTGGAGACGCAGTTTCCTGTTAA TGACAATAAATCCCTGCTCCCCCTGCCTCAGACATCTACGCAGCGAAATCGAGCCTGGCCTTGAGGGTCCACACCGCGAGGGAAGATGCG TGCGCCCATTCCAGAGCCTAAGCCTGGAGACCTGATTGAGATTTTTCGCCCTTTCTACAGACACTGGGCCATCTATGTTGGCGATGGATA TGTGGTTCATCTGGCCCCTCCAAGTGAGGTCGCAGGAGCTGGTGCAGCCAGTGTCATGTCCGCCCTGACTGACAAGGCCATCGTGAAGAA GGAATTGCTGTATGATGTGGCCGGGAGTGACAAGTACCAGGTCAACAACAAACATGATGACAAGTACTCGCCGCTGCCCTGCAGCAAAAT CATCCAGCGGGCGGAGGAGCTGGTGGGGCAGGAGGTGCTCTACAAGCTGACCAGTGAGAACTGCGAGCACTTTGTGAATGAGCTGCGCTA TGGAGTCGCCCGCAGTGACCAGGCTTATGTACAGAAGTACGTCGTGAAGAATTATTTCTACTATTACCTATTCCAATTTTCAGCTGCTTT GGGCCAAGAAGTGTTCTACATCACGTTTCTTCCATTCACTCACTGGAATATTGACCCTTATTTATCCAGAAGATTGATCATCATATGGGT TTTGGTGATGTATATTGGCCAAGTGGCCAAGGATGTCTTGAAGTGGCCCCGTCCCTCCTCCCCTCCAGTTGTAAAACTGGAAAAGAGACT GATCGCTGAATATGGAATGCCATCCACCCACGCCATGGCGGCCACTGCCATTGCCTTCACCCTCCTTATCTCTACTATGGACAGATACCA GTATCCATTTGTGTTGGGACTGGTGATGGCCGTGGTGTTTTCCACCTTGGTGTGTCTCAGCAGGCTCTACACTGGGATGCATACGGTCCT GGATGTGCTGGGTGGCGTCCTGATCACCGCACTCCTCATCGTCCTCACCTACCCTGCCTGGACCTTCATCGACTGCCTGGACTCGGCCAG CCCCCTCTTCCCCGTGTGTGTCATAGTTGTGCCATTCTTCCTGTGTTACAATTACCCTGTTTCTGATTACTACAGCCCAACCCGGGCGGA CACCACCACCATTCTGGCTGCCGGGGCTGGAGTGACCATAGGATTCTGGATCAACCATTTCTTCCAGCTTGTATCCAAGCCCGCTGAATC TCTCCCTGTTATTCAGAACATCCCACCACTCACCACCTACATGTTAGTTTTGGGTCTGACCAAATTTGCAGTGGGAATTGTGTTGATCCT CTTGGTTCGTCAGCTTGTACAAAATCTCTCACTGCAAGTATTATACTCATGGTTCAAGGTGGTCACCAGGAACAAGGAGGCCAGGCGGAG ACTGGAGATTGAAGTGCCTTACAAGTTTGTTACCTACACATCTGTTGGCATCTGCGCTACAACCTTTGTGCCGATGCTTCACAGGTTTCT GGGATTACCCTGAGTCTCAAACAGTTGGAAACTAGCCCACTGGACATGAAAGCCAAGACATAGGAAAGTTATTGGTAGGCAAATCTTGAC AACTTATTTTTCTTTAACAACAACAAAAAGTCATACGGCTGTCTTGCTACTACCAGATAAATGATGCTGCTGTGTGAAAGGAAGAACTGT CTCATAGCGGTCATTGGTCGTCCGTGGTGGTTGGTTGTGCTACAGTTGAACCCAGGCTAAAGACCATAATCCGGATCTTTAAAGGCACAC ACCGCGCCCCCCCCCCCCCCGCCCGGCCCCTGCTCCTCTCGCTGTTGCACGGGCTTTGGATCTAGTCATGGGCTGGCAGGAATTGTGGCC TGGCTTAGGAATAGCTATGAGCCCCACTGGGTTCTGGAGAGCCAGTAGAGATGGGGTGATCTGGGAGGCTGGAGGTAGAGCCTTTCTTTT CCGTTACAACCTTGCCTAGCATGGAGTTATTTCTAAAATGGGAACTTTGGTCTAGGAGAAGGGGTGGCACCATATGAAACGGCATTCCTT GGACAGGGTGACTTCCTTATCGTTTATTTGGTGATTTTTTGTTTTGTTTTGTTTGAGACAGGATCTTGCTCTGTTTCCCAGGCTGTATTA CAGTGGCACAATCTCAGCTCACTGCAAACTCTGCCTCCCGGGCTCAAGCAATCCTCCTGCCTGAGCCAACTGAGTAGCTGGGACTGTAAG CATAGACCACCATGTGCCCAGCTAATTTTTGTAGAGACAGGGTTTCTCCATGTTGCCCAGGTACGTCTGAAACTCCTGGGCTTAAGTGAT CCACCCACCTCAGCCTCCCAAAGTGCTGGGATTATAGGCATGAGCCACTGTGCCCGGCCTCCTCCTTGTTATGATCAAATTAGACTGTGC CTGGTTGGGTGGTAAGATCACTCTGAAAGAAAGCTCACTGTGAAGAGATGAAAGGTGGAGGCAGAGCTGTGAGGTCATGGGGAAAAGCCT GCTTTCCTTATAAGTCCTGCTGTTCATGTTGGAATAAGGATCTGCTCTTCCTTGTTTCCATGCATTTTGCAGGATTCCAGGTACCATTAC CACACTCTTCTGACCCATGAAACCAACTGGCTGCTCACACATCACCAAACAGGTTGGGGGTTAGCCTTCAGCACAGGTGGATACATCTGG GATTCACTGAGATTCCTGCCCTCTCCTGCTTCCTAGTGGTTTGGGACAGGCCCTCTGCCCATCGTCAGCAGTTTTTTGCTTTCATACAAA CCTGGAAGGCACTGGCATCTGCCTAGGAAAGTGGATCTGTGAAGAACAGATGAACTCAATCCTTTCTGGAGTCTGACAAAGAAGGGATAG GCTTCCTTGACATTGCCTGTCCTGACAAGGCCTCCCTGACATTACTCCTCCAATTTCACAGTTACCTTCTGTAAATCTATTTTCTCATCT ACTGAATAGAATCAGGCGCCCTTTTTGTCTTCCCACCTCTTATCTCTTGGCAATTTTAAGGGGAATTAATGCAAGAACAACTTTAGTGTC TCTTGGGAAAACAAGCCAACCAAATACAAAACCCATTAAGCCTACTAGGGTGAGTCCTCTTAACATGGGAAGGCGATGATTATGCAAACA CCGGAGTTCCCTCCTCTTCAGTTCCTAAGAATAAAGAACAGGTATCAAGAACTTTCTTTAAAGTTAGTGTAACTATAGTTAACAAAGTAT CCATTGAAGTTTAGTGCCTGTAGGACTGAGCCAGTGCTTTATCAACCCAACACATCATCACCATGTGCATACTCTAGAAAAAAAAATAGC TTCCTTAAAAGTTACAGAGGCTCTTAACGTGTTAAAACCGAAAAATCACATTTTTCTTGATTTCAAATATGTTCTACGGCCTTACTGTTG GGATGATATTTAGTATGTAACTTAGCATTCCAATTTCTCAAGAATTTTTAGGCCGGGTGCGGTGGCTCATGCCTGTAATCCCAGCACTTT |
Top |
FusionGenePPI for PLA2G16_SGPP2 |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
PLA2G16 | UBQLN1, UBQLN4, PPP2R1A, HRAS | SGPP2 |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for PLA2G16_SGPP2 |
![]() (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for PLA2G16_SGPP2 |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |